Xilio Therapeutics Inc.
XLO | NASDAQ
$9.04
+$0.02 (+0.22%)
At close: Sep 22, 2026, 4:00 PM ET
$9.04
$0 (0.00%)
After-hours:
Sep 22, 2026, 4:10 PM ET
Market Data
Market Cap $59.31M
Enterprise Value $-70.43M
Beta -0.12
Average Volume 38.52K
Shares Outstanding (Diluted) 19.4M
Shares Change YoY 424.17%
Institutional Ownership 13.50%
Exchange NASDAQ
ISIN US98422T2096
Price Performance
Price Change 1M -3.2%
Price Change 3M 1.4%
Price Change 6M 5.7%
Price Change YTD -4.0%
Price Change 1Y -15.8%
Price Change 3Y -71.0%
Price Change 5Y -96.0%
1M CAGR (ann.) -1.6%
1Y CAGR (ann.) -15.6%
5Y CAGR (ann.) N/A
All-Time CAGR -48.0%
Valuation
PE Ratio -5.50
Forward PE 1.54
PEG Ratio -0.03
Forward PEG 0.44
PS Ratio 0.93
Forward PS 2.20
PB Ratio 0.82
P/FCF Ratio -0.97
P/Adj. FCF Ratio -0.86
P/OCF Ratio -2.89
EV/Sales -1.10
EV/EBIT 3.23
EV/EBITDA 3.44
EV/FCF 1.15
Earnings Yield -18.2%
FCF Yield -103.3%
Adj. FCF Yield -116.6%
Financial Health
Net Cash $136.04M
Total Debt $6.3M
Cash & Short-Term Investments $136.04M
Total Assets $154.25M
Current Ratio 4.25
Quick Ratio 4.25
Debt / Equity Ratio 0.09
Debt / EBITDA -0.31
Debt / FCF -0.10
OCF / Debt -9.61
Interest Coverage 0.00
Altman Z-Score -2.70
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 99.5%
Operating Profit Margin -48.9%
EBITDA Margin -32.0%
Net Profit Margin -34.1%
FCF Margin -95.6%
Adj. FCF Margin -107.9%
SBC / Revenue 12.3%
SBC Impact (per share) -12.8%
Returns
Return on Assets -14.2%
Return on Equity -50.8%
Return on Invested Capital -25.8%
Return on Capital Employed -26.1%
Return on Tangible Assets -14.2%
Historical Growth (CAGR)
Revenue CAGR 3Y 113.7%
Revenue CAGR 5Y 87.9%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 96.7%
EPS CAGR 5Y 82.4%
EPS CAGR 10Y N/A
FCF CAGR 3Y -71.3%
FCF CAGR 5Y 19.7%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 3
EPS Growth Next 3Y -29.5%
Revenue Growth Next 3Y -61.7%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$0.82
EPS Growth Est (next Q) -46.8%
Revenue Est (next Q) $4.84M
Revenue Growth Est (next Q) -74.6%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $98
Price Target Upside 986.5%
Cash Flow
Operating Cash Flow $-60.6M
Free Cash Flow $-61.27M
Adj. Free Cash Flow $-69.13M
FCF Per Share -$3.16
OCF Per Share -$3.12
OCF/S Ratio -94.5%
Income Statement
Revenue $64.09M
Gross Profit $63.75M
Operating Income $-31.37M
EBITDA $-20.49M
Net Income $-21.83M
EPS (Diluted) -$1.64
Revenue / Employee $843.32K
Profit / Employee $-287.22K
Employees 76
Add to Watchlist
Select watchlists to add or remove XLO